Zhou Jun, Deng Wei, Gao Jing, Yuan Jiajia, Li Yanyan, Shen Lin
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Feb;18(2):123-6.
To investigate the association between ABCB1 polymorphisms and chemosensitivity of paclitaxel in Chinese advanced gastric cancer(AGC) patients.
Clinical data and peripheral blood prior to chemotherapy of 412 AGC patients treated with first-line capecitabine plus paclitaxel(pactitaxel group, n=268) or cisplatin(cisplatin group, n=268) in Peking University Cancer Hospital from December 2008 to April 2013 were retrospectively collected. ABCB1 G2677T/A polymorphisms were determined using PCR amplification and Sanger Sequencing. Clinical response evaluation and survival analysis were performed using RECIST1.1 criteria and Kaplan-Meier curve, respectively. The associations of ABCB1 G2677T/A polymorphisms with clinical response and survival were analyzed statistically.
The genotypes of ABCB1 were detected in all the patients and the frequency of wild type(G2677G), single allele variants(G2677T+G2677A), and two allele variants (T2677T+T2677A+A2677A) was 22.8%(94/412), 49.8%(205/412), and 27.4%(113/412), respectively. In paclitaxel group, the disease control rate(DCR)[89.9%(116/129)] and median progression-free survival(PFS)(190 days) of patients with single allele variants of G2677T/A were significantly higher than those of wild type patients[76.1%(51/67) and 110 days, all P<0.05], and did not differ statistically from those with two allele variants. In cisplatin group, no significant differences were observed among patients with different genotypes of ABCB1 in terms of the DCR or PFS(all P>0.05).
ABCB1 G2677T/A polymorphisms are associated with chemosensitivity of paclitaxel in gastric cancer.
探讨ABCB1基因多态性与中国晚期胃癌（AGC）患者对紫杉醇化疗敏感性之间的关系。
回顾性收集2008年12月至2013年4月在北京大学肿瘤医院接受一线卡培他滨联合紫杉醇治疗（紫杉醇组，n = 268）或顺铂治疗（顺铂组，n = 268）的412例AGC患者化疗前的临床资料和外周血。采用PCR扩增和Sanger测序法检测ABCB1基因G2677T/A多态性。分别采用RECIST1.1标准和Kaplan-Meier曲线进行临床疗效评估和生存分析。对ABCB1基因G2677T/A多态性与临床疗效和生存的相关性进行统计学分析。
所有患者均检测到ABCB1基因的基因型，野生型（G2677G）、单等位基因突变型（G2677T + G2677A）和双等位基因突变型（T2677T + T2677A + A2677A）的频率分别为22.8%（94/412）、49.8%（205/412）和27.4%（113/412）。在紫杉醇组中，G2677T/A单等位基因突变型患者的疾病控制率（DCR）[89.9%（116/129）]和中位无进展生存期（PFS）（190天）显著高于野生型患者[76.1%（51/67）和110天，均P < 0.05]，且与双等位基因突变型患者无统计学差异。在顺铂组中，ABCB1基因不同基因型患者的DCR或PFS均无显著差异（均P > 0.05）。
ABCB1基因G2677T/A多态性与胃癌患者对紫杉醇的化疗敏感性相关。
